Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BNTC
BNTC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BNTC News
Benitec Q3 Earnings Beat Expectations
May 14 2026
seekingalpha
Latest Wall Street Ratings Overview
May 12 2026
CNBC
Seaport Therapeutics Appoints Dr. Sharon Mates to Board of Directors
Apr 27 2026
Newsfilter
Benitec Biopharma Showcases BB-301 Clinical Results at MDA Conference
Mar 10 2026
Newsfilter
Benitec Reports Q2 Earnings Miss with Strategic Upgrade
Feb 12 2026
seekingalpha
Significant Progress in BB-301 Clinical Trials
Feb 12 2026
Newsfilter
Benitec Biopharma Announces Financial Results for Q2 2026 and Offers Operational Update
Feb 12 2026
moomoo
Benitec Biopharma Reports Q2 EPS of USD -0.26
Feb 12 2026
moomoo
Benitec Biopharma Reports Q2 Operating Loss of USD 13.4 Million
Feb 12 2026
moomoo
Benitec Biopharma Reports Q2 Net Loss of USD 11.8 Million
Feb 12 2026
moomoo
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
Jan 16 2026
NASDAQ.COM
Benitec Biopharma Reports Positive Long-Term Results for BB-301 in OPMD Treatment
Jan 11 2026
NASDAQ.COM
Benitec's BB-301 Therapy Shows Significant Improvement in Dysphagia
Jan 11 2026
Globenewswire
Wall Street Analysts Forecast an 87.48% Increase for Benitec Biopharma (BNTC): Key Insights to Consider
Dec 05 2025
NASDAQ.COM
Benitec Biopharma Inc. Reveals Pricing for $100 Million Common Stock Sale
Nov 06 2025
Newsfilter
HC Wainwright & Co. Reaffirms Buy Rating for Benitec Biopharma and Increases Price Target to $35
Nov 04 2025
Benzinga
Show More News
